Внебольничная пневмония у взрослых: современные подходы к диагностике, антибактериальной терапии и профилактике (по материалам согласительных рекомендаций Американского общества инфекционистов / Американского торакального общества, 2007)

1. Mandell L.A., Niederman M.S. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Canadian Community-Acquired Pneumonia Consensus Conference Group. Can. J. Infect. Dis. 1993; 4: 25–51.

2. Niederman M.S., Bass J.B., Campbell G.D. et al. Guidelines for the initial empiric therapy of community-acquired pneumonia: proceedings of an American Thoracic Society Consensus Conference. Am. Rev. Respir. Dis. 1993; 148: 1418–1426.

3. Niederman M.S., Mandell L.A., Anzueto A. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730–1754.

4. Heffelfinger J.D., Dowell S.F., Jorgensen J.H. et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 2000; 160: 1399–1408

5. Bartlett J.D., Dowell S.F., Mandell L.A. et al. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2000; 31: 347–382.

6. Mandell L.A., Marrie T.J., Grossman R.E. et al. Canadian guidelines for the initial management of communityacquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 2000; 31: 383–421.

7. Grupo de Trabajo de Asociacion Latinoamericana del Torax (ALAT). Recomendaciones ALAT sobre la neumonia adquirida en la communidad. Arch. Bronconeumol. 2001; 37: 340–348.

8. Working Groups of the South African Pulmonology Society and the Antibiotic Study Group of South Africa. Management of community-acquired pneumonia in adults. S. Afr. Med. J. 1996; 86: 1152–1163.

9. Management of community0acquired pneumonia in adults. S. Afr. Med. J. 2007; 97: 1295–1306.

10. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br. J. Hosp. Med. 1993; 49: 346–350.

11. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (suppl. IV): 1–64.

12. BTS Guidelines for the management of community acquired pneumonia in adults – 2004 update. www.brit-thoracic.org.uk

13. Huchon G., Woodhead M., the European Respiratory Society Task Force. Guidelines for management of adult community-acquired lower respiratory tract infections. European Study on Community-acquired Pneumonia (ESOCAP) Committee. Eur. Respir. J. 1998; 11: 986–991.

14. Dorca J., Bello S., Blanquer J. et al. Diagnostico y tratamiento de la neumonia adguirida en la comunidad. Arch. Bronconeumol. 1997; 33: 240–246.

15. Paul Ehrlich Society for Chemotherapy and the German Respiratory Association. Rational treatment of bacterial respiratory tract infections. Chemother. J. 2000; 9: 3–23.

16. Guidelines of Infectious Diseases French Society. What should the initial antibiotic therapy for acute community-acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and resistance of pneumococci? Should combined treatment be used? Med. Mal. Infect. 2001; 31: 357–363.

17. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 2005; 26: 1138–1180.

18. Memish Z.A., Shibl A.M., Ahmed Q.A.A., The Saudi Arabian Community0Acquired pneumonia Working Group (SACAPWG). Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Int. J. Antimicrob. Agents 2002; 20: 1–12.

19. Matsushima T., Kohno S., Saito A. et al. Diagnostic and treatment guideline for community-acquired pneumonia. Tokyo: Japanese Respiratory Society, General Managing Director Ando Massayuki; 2000. Int. J. Antimicrob. Agents 2001; 18: 45–48.

20. Philippine Practice Guidelines Group in Infectious Diseases. Diagnosis, empiric management and prevention of community-acquired pneumonia in immunocompetent adults. Quezon City, Philippines: Philippine Society for Microbiology and Infectious Diseases; 1998.

21. Ho P.L., Wong S.S.Y. Reducing bacterial resistance with International multi-discipliniary programme on antimicrobial chemotherapy. 2nd ed. Hong Kong: Hong Kong University and Hong Kong Hospital Authority; 2001. 34–35.

22. Ministry of Health, National Medical Research Council, Chapter of Physicians Academy of Medicine Singapore. Clinical practice guidelines. Use of antibiotics in adults. Singapore; 2000.

23. Anonymous. Therapeutic guidelines: antibiotic (version 11). North Melbourne: Therapeutic Guidelines; 2000.

24. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин. микробиол. и антимикроб. химиотер. 2003; 5: 198–224.

25. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин. микробиол. и антимикроб. химиотер. 2006; 8: 54–86.

26. Ewig S., Ruiz M., Mensa J. et al. Severe communityacquired pneumonia: assessment of severity criteria. Am. J. Respir. Crit. Care Med. 1998; 158: 1102–1108.

27. van der Eerden M.M., Vlaspolder F., de Graaff C.S. et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672–678.

28. Musher D.M., Montoya R., Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 2004; 39: 165–169.

29. de Roux A., Marcos M.A., Garcia E. et al. Viral communityacquired pneumonia in nonimmunocompromised adults. Chest 2004; 125: 1343–1351.

30. Yu V.L., Chiou C.C., Feldman C. et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 2003; 37: 230–237.

31. Leroy O., Saux P., Bedos J.P., Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–183.

32. File T.M. Community-acquired pneumonia. Lancet 2003; 362: 1991–2001.

33. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America: controlling tuberculosis in the United States. Am. J. Respir. Crit. Care Med. 2005; 172: 1169–227.

34. Amsden G.W. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 2005; 55: 10–21.

35. Tamaoki J., Kadota J., Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am. J. Med. 2004; 117 (suppl. 9A): 5S–11S.

36. Martinez J.A., Horcajada J.P., Almela M. et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 2003; 36: 389–395.

37. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 2001; 161: 1837–1842.

38. Nicholson K.G., Aoki F.Y., Osterhaus A.D. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–1850.

39. Kaiser L., Wat C., Mills T. et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 2003; 163: 1667–1672.

40. Jefferson T., Demicheli V., Rivetti D. et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 303–313.

41. Hien T.T., de Jong M., Farrar J. Avian influenza-a challenge to global health care structures. N. Engl. J. Med. 2004; 351: 2363–2365.

42. Chotpitayasunondh T., Ungchusak K., Hanshaoworakul W. et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 2005; 11: 201–209.

43. Available at: http://www.pandemicflu.gov

44. World Health Organization. Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses: interim biosafety assessment. Available at: http://www.who.int/csr/resources/publications/influenza/. Accessed 16 January 2007.

45. Houck P.M., Bratzler D.W., Nsa W. et al. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 2004; 164: 637–644.

46. Meehan T.P., Fine M.J., Krumholz H.M. et al. Quality of care, process, and outcomes in elderly patients with pneumonia. J. A. M. A. 1997; 278: 2080–2084.

47. Benenson R., Magalski A., Cavanaugh S., Williams E. Effects of pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med. 1999; 6: 1243–1248.

48. Marrie T.J., Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260–1270.

49. Ramirez J.A., Srinath L., Ahkee S. et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 1995; 155: 1273–1276.

50. Halm E.A., Fine M.J., Marrie T.J. et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. J. A. M. A. 1998; 279: 1452–1457.

51. Menendez R., Torres A., Rodríguez de Castro F. et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin. Infect. Dis. 2004; 39: 1783–1790.

52. Castro0Guardiola A., Viejo0Rodriguez A.L., Soler0Simon S. et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am. J. Med. 2001; 111: 367–374.

53. Halm E.A., Fine M.J., Kapoor W.N. et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch. Intern. Med. 2002; 162: 1278–1284.

54. Dunbar L.M., Wunderink R.G., Habib M.P. et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 2003; 37: 752–760.

55. Rizzato G., Montemurro L., Fraioli P. et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur. Respir. J. 1995; 8: 398–402.

56. Schonwald S., Skerk V., Petricevic I. et al. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 1991; 10: 877–880.

57. Tellier G., Niederman M.S., Nusrat R. et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 2004; 54: 515–523.

58. Ely E.W., Laterre P.F., Angus D.C. et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit. Care Med. 2003; 31: 12–19.

59. Opal S.M., Garber G.E., LaRosa S.P. et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin. Infect. Dis. 2003; 37: 50–58.

60. Laterre P.F., Garber G., Levy H. et al. Severe communityacquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. 2005; 33: 952–961.

61. Annane D., Sebille V., Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J. A. M. A. 2002; 288: 862–871.

62. Torres A., Ewig S., El0Ebiary M. et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur. Respir. J. 1999; 14: 218–220.

63. Confalonieri M., Urbino R., Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. 2005; 171: 242–248.

64. Marik P., Kraus P., Bribante J. et al. Hydrocortisone and tumour necrosis factor in severe community acquired pneumonia. Chest 1993; 104: 389–392.

65. Ferrer M., Esquinas A., Leon M. et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am. J. Respir. Crit. Care Med. 2003; 168: 1438–1444.

66. Confalonieri M., Potena A., Carbone G. et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation. Am. J. Respir. Crit. Care Med. 1999; 160: 1585–1591.

67. Brochard L., Mancebo J., Wysocki M. et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1995; 333: 817–822.

68. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N. Engl. J. Med. 2000; 342: 1301–1308.

69. Dellinger R.P., Carlet J.M., Masur H. et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2004; 32: 858–873.

70. Roson B., Carratala J., Fernandez0Sabe N. et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 2004; 164: 502–508.

71. Menendez R., Torres A., Zalacain R. et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960–965.

72. Arancibia F., Ewig S., Martinez J.A. et al. Antimicrobial treatment failures in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2000; 162: 154–160.

73. Almirall J., Bolibar I., Vidal J. et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur. Respir. J. 2000; 15: 757–763.

74. Sanyal S., Smith P.R., Saha A.C. et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 1999; 160: 346–348.

75. Mortensen E.M., Coley C.M., Singer D.E. et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch. Intern. Med. 2002; 162: 1059–1064.

76. Ewig S., de Roux A., Bauer T. et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59: 421–427.

77. Halm E.A., Fine M.J., Marrie T.J. et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications forpractice guidelines. J. A. M. A. 1998; 279: 1452–1457.

78. Daifuku R., Movahhed H., Fotheringham N. et al. Time to resolution of morbidity: an endpoint for assessing the clinical cure of community-acquired pneumonia. Respir. Med. 1996; 90: 587–592.

79. Mittl R.L. Jr., Schwab R.J., Duchin J.S. et al. Radiographic resolution of community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 1994; 149: 630–635.

80. El Solh A.A., Pietrantoni C., Bhat A. et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am. J. Respir. Crit. Care Med. 2003; 167: 1650–1654.

81. Metersky M.L., Ma A., Bratzler D.W., Houck P.M. Predicting bacteremia in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2004; 169: 342–347.

82. Smith M.D., Derrington P., Evans R. et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J. Clin. Microbiol. 2003; 41: 2810–2813.

83. Navarro D., Garcia0Maset L., Gimeno C. et al. Performance of the Binax NOW Streptococcus pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the absence of acute pneumococcal infection. J. Clin. Microbiol. 2004; 42: 4853–4855.

84. Plouffe J.F., Breiman R.F., Fields B.S. et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin. Infect. Dis. 2003; 37: 1475–1480.

85. Harper S.A., Fukuda K., Uyeki T.M. et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. 2005; 54: 1–40.

86. Shapiro E.D., Berg A.T., Austrian R. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 1991; 325: 1453–1460.

87. Farr B.M., Johnston B.L., Cobb D.K. et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch. Intern. Med. 1995; 155: 2336–2340.

88. Jackson L.A., Neuzil K.M., Yu O. et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 2003; 348: 1747–1755.

89. Whitney C.G., Farley M.M., Hadler J. et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N. Engl. J. Med. 2003; 348: 1737–1746.

90. Flannery B., Schrag S., Bennett N.M. et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. J. A. M. A. 2004; 291: 2197–2203.

91. Gross P.A., Hermogenes A.W., Sacks H.S. et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Intern. Med. 1995; 123: 518–527.

92. Jefferson T., Rivetti D., Rivetti A. et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366: 1165–1174.

93. Nichol K.L., Nordin J., Mullooly J. et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 2003; 348: 1322–1332.

94. Public health and aging: influenza vaccination coverage among adults aged ≥ 50 years and pneumococcal vaccination coverage among adults aged ≥ 65 years-United States, 2002. Morbid. Mortal. Wkly Rep. 2003; 52: 987–992.

95. Ward J.I., Cherry J.D., Chang S.J. et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 2005; 353: 1555–1563.

96. Nuorti J.P., Butler J.C., Farley M.M. et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. Engl. J. Med. 2000; 342: 681–689.

97. Marston B.J., Lipman H.B., Breiman R.F. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch. Intern. Med. 1994; 154: 2417–2422.

98. Centers for Disease Control and Prevention (CDC). Respiratory hygiene / cough etiquette in health-care settings. Available at: http://www.cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm. Accessed 16 January 2007.

99. Garner J.S. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect. Control. Hosp. Epidemiol. 1996; 17: 53–80.